参考文献/References:
[1] Li Y,Teng D,Ba J,et al.Efficacy and safety of long-term universal salt iodization on thyroid disorders:epidemiological evidence from 31 provinces of mainland China [J].Thyroid,2020,30(4):568-579.DOI:10.1089/thy.2019.0067.
[2] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南 [J].中华内分泌代谢杂志,2012,28(10):779-797.DOI:10.3760/cma.j.issn.1000-6699.2012.10.002.
[3] Durante C,Grani G,Lamartina L,et al.The diagnosis and management of thyroid nodules:a review [J].JAMA,2018,319(9):914-924.DOI:10.1001/jama.2018.0898.
[4] Haugen BR,Alexander EK,Bible KC,et al.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[5] Lin JS,Bowles EJA,Williams SB,et al.Screening for thyroid cancer:updated evidence report and systematic review for the US preventive services task force [J].JAMA,2017,317(18):1888-1903.DOI:10.1001/jama.2017.0562.
[6] Lee JY,Baek JH,Ha EJ,et al; Korean Society of Thyroid Radiology(KSThR)and Korean Society of Radiology.2020 Imaging Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer:Korean Society of Thyroid Radiology [J].Korean J Radiol,2021,22(5):840-860.DOI:10.3348/kjr.2020.0578.
[7] 中华医学会超声医学分会浅表器官和血管学组,中国甲状腺与乳腺超声人工智能联盟.2020甲状腺结节超声恶性危险分层中国指南:C-TIRADS [J].中华超声影像学杂志,2021,30(3):185-200.DOI:10.3760/cma.j.cn131148-20210205-00092.
[8] Leenhardt L,Erdogan MF,Hegedus L,et al.2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer [J].Eur Thyroid J,2013,2(3):147-159.DOI:10.1159/000354537.
[9] Kwak JY,Han KH,Yoon JH,et al.Thyroid imaging reporting and data system for US features of nodules:a step in establishing better stratification of cancer risk [J].Radiology,2011,260(3):892-899.DOI:10.1148/radiol.11110206.
[10] Hu Y,Xu S,Zhan W.Diagnostic performance of C-TIRADS in malignancy risk stratification of thyroid nodules:a systematic review and meta-analysis [J].Front Endocrinol(Lausanne),2022,13:938961.DOI:10.3389/fendo.
[11] Ito Y,Amino N,Yokozawa T,et al.Ultrasonographic evaluation of thyroid nodules in 900 patients:comparison among ultrasonographic,cytological,and histological findings [J].Thyroid,2007,17(12):1269-1276.DOI:10.1089/thy.2007.0014.
[12] Cibas ES,Ali SZ.The 2017 Bethesda System for Reporting Thyroid Cytopathology [J].Thyroid,2017,27(11):1341-1346.DOI:10.1089/thy.2017.0500.
[13] Fnais N,Soobiah C,Al-Qahtani K,et al.Diagnostic value of fine needle aspiration BRAF(V600E)mutation analysis in papillary thyroid cancer:a systematic review and meta-analysis [J].Hum Pathol,2015,46(10):1443-1454.DOI:10.1016/j.humpath.
[14] Amin MB,Edge SB,Greene FL.AJCC cancer staging manual,eighth Edition [M].NewYork:Springer,2017.
[15] Baloch ZW,Asa SL,Barletta JA,et al.Overview of the 2022 WHO classification of thyroid neoplasms [J].Endocr Pathol,2022,33(1):27-63.DOI:10.1007/s12022-022-09707-3.
[16] Park S,Kim WG,Han M,et al.Thyrotropin suppressive therapy for low-risk small thyroid cancer:a propensity score-matched cohort study [J].Thyroid,2017,27(9):1164-1170.DOI:10.1089/thy.2017.0177.
[17] Scharpf J,Tuttle M,Wong R,et al.Comprehensive management of recurrent thyroid cancer:An American Head and Neck Society consensus statement:AHNS consensus statement [J].Head Neck,2016,38(12):1862-1869.DOI:10.1002/hed.24513.
[18] Tufano RP,Clayman G,Heller KS,et al; American Thyroid Association Surgical Affairs Committee Writing Task Force.Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer:a critical review of the risks and benefits of surgical intervention versus active surveillance [J].Thyroid,2015,25(1):15-27.DOI:10.1089/thy.2014.0098.
[19] Mazzaferri EL,Jhiang SM.Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [J].Am J Med,1994,97(5):418-428.DOI:10.1016/0002-9343(94)90321-2.
[20] Ruegemer JJ,Hay ID,Bergstralh EJ,et al.Distant metastases in differentiated thyroid carcinoma:a multivariate analysis of prognostic variables [J].J Clin Endocrinol Metab,1988,67(3):501-508.DOI:10.1210/jcem-67-3-501.
[21] 张浩,孙威,田文.分化型甲状腺癌基础研究热点及未来方向 [J].中国实用外科杂志,2021,41(1):76-79.DOI:10.19538/j.cjps.issn1005-2208.2021.01.13.
[22] Eustatia-Rutten CF,Romijn JA,Guijt MJ,et al.Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma [J].J Clin Endocrinol Metab,2003,88(7):3184-3189.DOI:10.1210/jc.2003-030231.
[23] Suh CH,Baek JH,Choi YJ,et al.Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer:a systematic review and meta-analysis [J].Thyroid,2016,26(3):420-428.DOI:10.1089/thy.2015.0545.
[24] Zhao Q,Tian G,Kong D,et al.Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers [J].J Endocrinol Invest,2016,39(8):909-916.DOI:10.1007/s40618-016-0450-8.
[25] d'Herbomez M,Lion G,Béron A,et al.[Advances in thyroglobulin assays and their impact on the management of differentiated thyroid cancers] [J].Ann Biol Clin(Paris),2016,74(1):21-27.DOI:10.1684/abc.2015.1106.
[26] Loh TP,Chong HW,Kao SL.Thyroglobulin and thyroglobulin autoantibodies:interpret with care [J].Endocrine,2014,46(2):360-361.DOI:10.1007/s12020-013-0103-z.
[27] Chambon G,Alovisetti C,Idoux-Louche C,et al.The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders:results from 2733 consecutive patients [J].J Clin Endocrinol Metab,2011,96(1):75-81.DOI:10.1210/jc.2010-0162.
[28] Grant EG,Tessler FN,Hoang JK,et al.Thyroid Ultrasound Reporting Lexicon:White Paper of the ACR Thyroid Imaging,Reporting and Data System(TIRADS)Committee [J].J Am Coll Radiol,2015,12(12 Pt A):1272-1279.DOI:10.1016/j.jacr.2015.07.011.
[29] Ito Y,Miyauchi A,Inoue H,et al.An observational trial for papillary thyroid microcarcinoma in Japanese patients [J].World J Surg,2010,34(1):28-35.DOI:10.1007/s00268-009-0303-0.
[30] Ito Y,Miyauchi A,Kihara M,et al.Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation [J].Thyroid,2014,24(1):27-34.DOI:10.1089/thy.2013.0367.
[31] Bernardi S,Palermo A,Grasso RF,et al.Current status and challenges of US-guided radiofrequency ablation of thyroid nodules in the long term:a systematic review [J].Cancers(Basel),2021,13(11):2746.DOI:10.3390/cancers13112746.
[32] 中国医师协会超声医师分会.甲状腺微小乳头状癌热消融诊疗指征专家共识 [J].中华医学超声杂志(电子版),2019,16(8):571-574.DOI:10.3877/cma.j.issn.1672-6448.2019.08.004.
[33] 中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,等.甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版)[J].中国肿瘤,2018,27(10):768-773.DOI:10.11735/j.issn.1004-0242.2018.10.A006.
[34] Kim JH,Baek JH,Lim HK,et al.2017 Thyroid Radiofrequency Ablation Guideline:Korean Society of Thyroid Radiology [J].Korean J Radiol,2018,19(4):632-655.DOI:10.3348/kjr.2018.19.4.632.
[35] Orloff LA,Noel JE,Stack BC,Jr,et al.Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease:An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery,Associazione Medici Endocrinologi,British Association of Endocrine and Thyroid Surgeons,European Thyroid Association,Italian Society of Endocrine Surgery Units,Korean Society of Thyroid Radiology,Latin American Thyroid Society,and Thyroid Nodules Therapies Association [J].Head Neck,2022,44(3):633-660.DOI:10.1002/hed.26960.
[36] Mauri G,Hegedüs L,Bandula S,et al.European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions [J].Eur Thyroid J,2021,10(3):185-197.DOI:10.1159/000516469.